Hoogrisico mammacarcinoom, fase III, BRCA-like, neoadjuvante chemotherapie
HNSCC, fase I/II, CPS≥1, petosemtamab
Endometriumcarcinoom, fase III, dMMR, pembrolizumab
Sarcomen, fase I, radiotherapie, DDR remmers
Salivary duct carcinoom, fase II, dutasteride en CAB
Hormoongevoelig mammacarcinoom, fase III, immunotherapie
mCRPC, fase I, immunotherapie
Neuro-endocrien prostaatcarcinoom, fase Ib/II, immuuntherapie
mCRPC, fase II, immunotherapie
Melanoom stadium III, fase III, neo-adjuvante immuuntherapie
Deze website maakt gebruik van cookies.
